What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait

Photo: Karen Weintraub for Endpoints News June 2, 2026 12:00 PM EDT R&D What’s next for VEGF? AS­CO of­fered clues, but an­swers will have to wait Max Gelman Senior Editor CHICA­GO — Not long ago, there were hopes that a new class of can­cer drugs would re­peat the suc­cess of Keytru­da. In­stead, it seems more like­ly … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER